Article Listing - CoCensys Sales Force Ahead Of Schedule

EXPANDED PHASE II STUDY FOR TLC G-65

16 March 1992

The Liposome Co reports that it has initiated an expanded Phase II trial with its proprietary TLC G-65 for the...

ROFERON-A COULD SAVE SIGHT

16 March 1992

Swiss major Hoffmann-La Roche's Roferon-A (recombinant interferon alfa-2a) may prove to be a useful treatment for certain elderly patients who...

FOCUS ON JANSSEN'S RISPERDOL

16 March 1992

The forthcoming launch of Janssen's new potent combined 5-HT2/ dopamine D2 receptor antagonist antipsychotic Risperdol (risperidone) could represent a major...

ITALY'S RECORDATI SEEKS US CR PARTNER

16 March 1992

Speaking at a Mabon Securities' meeting in New York, the Italian drugmaker Recordati made it be known that it was...

$95 MILLION CAPITAL INFUSION FOR ROBERTS

16 March 1992

Yamanouchi Pharmaceuticals of Japan last month completed a previously-approved (Marketletter January 1 and 6) purchase of about 29% of the...

EURO MARKETS FOR PATIENT MONITORING

16 March 1992

The European market for patient monitoring consumables will continue to grow until the mid-1990s, from a value of just under...

FRENCH HEALTH SECTOR REFORMS

16 March 1992

Strong, domestically-owned companies with a high level of domestic investment, such as Rhone-Poulenc Rorer and Sanofi, will have less to...

UK PHARMACY STUDY URGES MORE OTCs

16 March 1992

A new report on the future of community pharmacy in the UK has called for an increase in the...

REPLIGEN APPOINTMENT

16 March 1992

- John Kenward takes the newly-created position of chief operating officer at Repligen.

ANALYST EMPLOYMENT MOVES

16 March 1992

- UK pharmaceuticals analyst Percy Lomax has joined Fleming, moving from Shep-pards. And Mark Tracey has moved from Paribas to...

Showing 94651-94660 of 95353 articles